Arthroscopic Treatment of Femoroacetabular Impingement Syndrome: An Updated Review.

Arthroscopic surgery Conservative treatment Femoroacetabular impingement Review Treatment outcome

Journal

Clinics in orthopedic surgery
ISSN: 2005-4408
Titre abrégé: Clin Orthop Surg
Pays: Korea (South)
ID NLM: 101505087

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 06 10 2023
revised: 18 01 2024
accepted: 18 01 2024
medline: 2 8 2024
pubmed: 2 8 2024
entrez: 2 8 2024
Statut: ppublish

Résumé

Treatment strategies for femoroacetabular impingement (FAI) syndrome have evolved in tandem with increased comprehension of FAI's impact on hip joint health. Early intervention, including arthroscopic surgery, has gained popularity due to its potential to delay the progression of osteoarthritis. Arthroscopic surgery has demonstrated significant efficacy in treating FAI syndrome, with robust evidence from randomized controlled trials and systematic reviews supporting its use. Despite arthroscopic surgery's success, complications and reoperations are not uncommon. The incidence ranges from 1% to 31% and 4% to 13%, respectively. Adjunctive biologic treatments, such as bone marrow aspirate concentrates and platelet-rich plasma, have shown promise in chondral lesion management. However, robust evidence supporting their routine use in FAI syndrome is currently lacking. Among conservative treatment methods, intra-articular injections offer diagnostic and therapeutic benefits for FAI patients. While they may provide pain relief and aid in prognosis, their long-term efficacy remains a subject of debate. Comparative studies between conservative and arthroscopic treatments highlight the importance of personalized approaches in managing FAI syndrome. In conclusion, recent advancements in FAI syndrome management have illuminated various treatment modalities. Arthroscopic surgery stands as a pivotal intervention, offering substantial benefits in pain relief, function, and quality of life. However, careful patient selection and postoperative monitoring are crucial for optimizing outcomes. Adjunctive biologics and intra-articular injections show promise but require further investigation. Tailoring treatment to individual patient characteristics remains paramount in optimizing FAI syndrome management.

Identifiants

pubmed: 39092294
doi: 10.4055/cios23307
pmc: PMC11262938
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

517-525

Informations de copyright

Copyright © 2024 by The Korean Orthopaedic Association.

Déclaration de conflit d'intérêts

CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported.

Auteurs

Jung-Wee Park (JW)

Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea.
Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.

Jung-Mo Hwang (JM)

Department of Orthopedic Surgery, Chungnam National University School of Medicine, Daejeon, Korea.

Jeong Joon Yoo (JJ)

Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea.
Department of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH